Literature DB >> 8695539

Current options in the management of gastrointestinal cancer.

G Middleton1, D Cunningham.   

Abstract

Surgery is the standard approach for localized gastrointestinal malignancy both in the upper GI tract and for cancer of the large bowel. Adjuvant chemotherapy following curatively resected colorectal cancer, results in a definite survival advantage. The use of chemotherapy in an attempt to downstage inoperable gastric cancer to allow for subsequent radical resection has yielded promising results. Likewise improved survival rate in patients treated with adjuvant chemotherapy after resection, justify further exploration of perioperative chemotherapy in operable gastric cancer. In squamous oesophageal cancer, modem chemo-radiation regimens are superior to radiotherapy alone in localized disease. Some series demonstrate impressive survival rates in the absence of surgical intervention raising the question as to the precise role of surgery in a combined modality approach. Ongoing randomized trials will clarify the relative contributions of these treatment modalities in the management of this disease. In metastatic disease of both upper GI and colonic tumours maintenance of good quality of life should be the primary endpoint. Randomised trials of chemotherapy against best supportive care have provided strong justification for the use of chemotherapy in the management of advanced gastric, pancreatic and colorectal cancer.

Entities:  

Mesh:

Year:  1995        PMID: 8695539     DOI: 10.1093/annonc/6.suppl_1.s17

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  10 in total

1.  Evaluation of dose coverage to target volume and normal tissue sparing in the adjuvant radiotherapy of gastric cancers: 3D-CRT compared with dynamic IMRT.

Authors:  Kk Murthy; Ka Shukeili; Ss Kumar; Ca Davis; Rr Chandran; S Namrata
Journal:  Biomed Imaging Interv J       Date:  2010-07-01

Review 2.  Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America.

Authors:  Greg Knight; Craig C Earle; Roxanne Cosby; Natalie Coburn; Youssef Youssef; Richard Malthaner; Rebecca K S Wong
Journal:  Gastric Cancer       Date:  2012-03-31       Impact factor: 7.370

Review 3.  Updates on esophageal and gastric cancers.

Authors:  Amy Gallo; Charles Cha
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

4.  Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells.

Authors:  Hideko Akagi; Hajime Higuchi; Hidetoshi Sumimoto; Toru Igarashi; Ayano Kabashima; Hiroyuki Mizuguchi; Motoko Izumiya; Gen Sakai; Masayuki Adachi; Shinsuke Funakoshi; Shoko Nakamura; Yasuo Hamamoto; Takanori Kanai; Hiromasa Takaishi; Yutaka Kawakami; Toshifumi Hibi
Journal:  Gastric Cancer       Date:  2012-04-24       Impact factor: 7.370

Review 5.  Gastric adenocarcinoma: review and considerations for future directions.

Authors:  Bryan J Dicken; David L Bigam; Carol Cass; John R Mackey; Anil A Joy; Stewart M Hamilton
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

6.  Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience.

Authors:  Philippe G Aftimos; Elie A Nasr; Dolly I Nasr; Roger J Noun; Fady L Nasr; Marwan G Ghosn; Joelle A El Helou; Georges Y Chahine
Journal:  Radiat Oncol       Date:  2010-06-04       Impact factor: 3.481

Review 7.  Gastric carcinoma.

Authors:  Alexandria T Phan; Jaffer A Ajani
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

8.  The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents.

Authors:  Dimitra Florou; Konstantinos Mavridis; Andreas Scorilas
Journal:  Tumour Biol       Date:  2012-09-05

9.  Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer.

Authors:  A B C Crumley; D C McMillan; M McKernan; A C McDonald; R C Stuart
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

10.  Neoadjuvant treatment for gastric cancer.

Authors:  Christoph Schuhmacher; Daniel Reim; Alexander Novotny
Journal:  J Gastric Cancer       Date:  2013-06-25       Impact factor: 3.720

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.